William Blair Has Negative Estimate for NAMS FY2025 Earnings

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) – Stock analysts at William Blair dropped their FY2025 earnings per share estimates for shares of NewAmsterdam Pharma in a research report issued to clients and investors on Wednesday, November 5th. William Blair analyst M. Phipps now anticipates that the company will earn ($1.54) per share for the year, down from their prior estimate of ($1.34). The consensus estimate for NewAmsterdam Pharma’s current full-year earnings is ($1.75) per share. William Blair also issued estimates for NewAmsterdam Pharma’s Q4 2025 earnings at ($0.40) EPS, Q1 2026 earnings at ($0.40) EPS, Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.41) EPS, Q4 2026 earnings at ($0.44) EPS, FY2026 earnings at ($1.65) EPS, FY2027 earnings at ($2.04) EPS and FY2028 earnings at ($1.71) EPS.

Several other equities research analysts have also issued reports on NAMS. Wells Fargo & Company began coverage on NewAmsterdam Pharma in a research note on Monday, August 25th. They issued an “overweight” rating and a $45.00 price objective for the company. HC Wainwright assumed coverage on shares of NewAmsterdam Pharma in a research report on Monday, October 20th. They set a “buy” rating and a $52.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Wednesday, October 8th. Needham & Company LLC increased their price objective on shares of NewAmsterdam Pharma from $40.00 to $46.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Finally, The Goldman Sachs Group began coverage on NewAmsterdam Pharma in a research note on Thursday, July 17th. They set a “neutral” rating and a $27.00 target price on the stock. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.30.

NewAmsterdam Pharma Stock Up 2.4%

NewAmsterdam Pharma stock opened at $39.89 on Monday. The company has a market cap of $4.49 billion, a PE ratio of -19.46 and a beta of 0.05. NewAmsterdam Pharma has a twelve month low of $14.06 and a twelve month high of $41.47. The company’s 50-day moving average price is $32.03 and its 200-day moving average price is $24.82.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.03). NewAmsterdam Pharma had a negative net margin of 627.59% and a negative return on equity of 28.30%. The business had revenue of $0.35 million for the quarter, compared to analysts’ expectations of $4.54 million.

Insider Activity at NewAmsterdam Pharma

In other news, Director James N. Topper acquired 1,260 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The shares were bought at an average price of $24.99 per share, with a total value of $31,487.40. Following the completion of the purchase, the director directly owned 3,027,864 shares in the company, valued at $75,666,321.36. This trade represents a 0.04% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Johannes Jacob Piete Kastelein sold 50,000 shares of the stock in a transaction on Thursday, August 21st. The stock was sold at an average price of $24.29, for a total value of $1,214,500.00. Following the transaction, the insider directly owned 119,302 shares in the company, valued at $2,897,845.58. The trade was a 29.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 226,342 shares of company stock worth $5,748,019. Company insiders own 20.84% of the company’s stock.

Hedge Funds Weigh In On NewAmsterdam Pharma

A number of large investors have recently bought and sold shares of the business. Quarry LP bought a new stake in NewAmsterdam Pharma during the 1st quarter valued at $25,000. Mather Group LLC. purchased a new position in NewAmsterdam Pharma in the third quarter valued at about $28,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in NewAmsterdam Pharma in the third quarter worth about $30,000. Wolverine Asset Management LLC purchased a new stake in shares of NewAmsterdam Pharma during the third quarter valued at about $69,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of NewAmsterdam Pharma by 18.0% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,337 shares of the company’s stock valued at $79,000 after buying an additional 662 shares during the last quarter. Institutional investors own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.